Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC). The findings were presented at the International Association for the Study of Lung Cancer (IASLC)…
The TAISHAN-302 trial revealed that tambotatug pelitecan (Tam-Peli) significantly improved overall survival, progression-free survival and objective response rate compared to topotecan in patients with relapsed small-cell lung cancer (SCLC). The randomized, open-label study enrolled 451 patients, with 225 receiving Tam-Peli and 226 receiving topotecan.
Tam-Peli reduced the risk of death by 54% and increased median overall survival by 4 months (13.3 months vs 9.4 months). It also improved progression-free survival by 71% (7.4 months vs 2.8 months) and response rate by 49.4% (59.1% vs 9.7%). The safety profile was manageable, with no new safety signals identified and no treatment-related deaths in the Tam-Peli group.
These results suggest Tam-Peli as a potential new standard-of-care option for second-line SCLC treatment.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
